Clinical trials: Tumor Infiltrating Lymphocytes, open to volunteers
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- (RIOT 4A) (NCT07192900)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- David Bartlett, MD
Breast Cancer Stage I, Triple Negative Breast Cancer (TNBC)
OPTImaL:Optimisation of Treatment for Patients With Low Stage Triple-negative Breast Cancer With High Stromal Tumor-infiltrating Lymphocytes
The aim of this study is to investigate whether subjects with breast cancer that have certain favorable features, after performing the surgery and radiation, the chemotherapy can be safely omitted in the treatment.
- Trial name
- OPTImaL (NCT06476119)
- Testing
- Adjuvant chemotherapy, No adjuvant chemotherapy
- Where
- 28 sites in Netherlands
- Volunteers
- 490 people
- Sponsor
- The Netherlands Cancer Institute
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Select Advanced Solid Tumors
A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1 is to find the recommended dose of KSQ-004EX to give to participants with advanced solid tumors. Phase 2 is to learn if KSQ-004EX at the recommended dose found in Phase1 can help to control advanced solid tumors.
- Trial name
- NCT06598371
- Testing
- Cyclophosphamide, Fludarabine, KSQ-004EX
- Where
- United States
- Volunteers
- 141 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC
TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy
This study evaluates the preliminary efficacy and safety of adjuvant therapy with liquid tumor-infiltrating lymphocytes (L-TIL) in combination with tislelizumab in patients with resectable stage II-IIIB non-small cell lung cancer…
- Trial name
- NCT07330037
- Testing
- L-TIL cells injection, Tislelizumab
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL
A Study of GC201 TIL in Advanced Gynecologic Tumors (10hospital)
This study is to investigate the safety and efficacy of signal switch receptor modified TIL (GC201 TIL) in patients with advanced gynecologic tumors.
- Conditions
- Advanced Gynecologic Tumors, Signal Switch Receptor Modified TIL, Treatment Side Effects, Effects of Immunotherapy
- Trial name
- NCT05098171
- Testing
- Signal Switch Receptor Modified TIL
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study of IOV-5001 in Adults With Advanced Solid Tumors
A Phase 1/2, multicenter, multi-cohort, open-label study of an autologous tumor-infiltrating lymphocytes (TIL) regimen with IOV-5001 in participants with previously treated advanced solid tumors
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
- Trial name
- NCT07743723
- Testing
- IOV-5001
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Melanoma
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
This is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma…
- Trial name
- NCT06961357
- Testing
- Cyclophosphamide, Fludarabine, Interleukin-2
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)
TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients
Aim of the study is to investigate the efficacy and safety of adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TIL) in patients with advanced pre-treated non-small cell lung cancer (NSCLC).
- Trial name
- BaseTIL-02L (NCT06455917)
- Testing
- TILs（Tumor Infiltrating Lymphocytes）
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Basel, Switzerland
Tumor Skin, Metastatic Melanoma
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
This is a study to investigate the safety and efficacy of an investigational OBX-115 regimen in adult participants with advanced solid tumors.
- Conditions
- Tumor Skin, Metastatic Melanoma, Melanoma, Lung Cancer
- Trial name
- Agni-01 (NCT06060613)
- Testing
- OBX-115
- Where
- 14 sites in United States, Australia
- Volunteers
- 254 people
- Sponsor
- Obsidian Therapeutics, Inc.
Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC)
Advanced Therapies for Liver Metastases
Liver metastases (MTS) are the main cause of death for patients affected by colorectal carcinoma (CRC) and pancreatic ductal adenocarcinoma (PDAC), thus representing the major unmet clinical need for these malignancies.
- Conditions
- Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis, IPMN, Pancreatic
- Trial name
- LiMeT (NCT04622423)
- Where
- Italy
- Volunteers
- 625 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Melanoma Metastatic
T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma
The purpose of this study is to assess wether it is safe and feasible to treat patients with tumor infiltrating lymphocytes that have been silenced for PD-1, using CRISPR-Cas9.
- Trial name
- CRISPR-TIL (NCT06783270)
- Testing
- TIL therapy
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- Inge Marie Svane
Gastric Cancer, Immunotherapy
The Construction of a Predictive Model for Gastric Cancer Immunotherapy Response Based on Tumor-Infiltrating Lymphocytes (TILs) and Histone H3K4me3 in the Tumor Microenvironment
Gastric cancer is one of the cancers with a high mortality rate globally, and its treatment outcomes urgently need to be improved.
- Trial name
- NCT07069842
- Testing
- Multiplex Immunofluorescence Technology, Co-Immunoprecipitation (Co-IP) Technology, Immunohistochemistry
- Where
- China
- Volunteers
- 170 people
- Sponsor
- Changzhi People's Hospital Affiliated to Changzhi Medical College
Advanced Solid Tumor
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor
Prospective, single-center, single-arm, open-label,interventional study evaluating adoptive cell therapy (ACT) with autologous tumor-infiltrating lymphocyte (TIL) infusion (HS-IT101) after lymphodepletion preparative with…
- Trial name
- NCT05539768
- Testing
- HS-IT101
- Volunteers
- 8 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Breast Cancer, Breast Carcinoma
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer
This Phase I/II study evaluates the safety and efficacy of autologous tumor-infiltrating lymphocytes (TIL) therapy combined with Pembrolizumab (Keytruda) immunotherapy in patients with advanced or metastatic refractory breast…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
- Trial name
- BAH249 (NCT06532812)
- Testing
- Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamid, Fludarabine
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Gastrointestinal Tumor
A Study of GC101 TIL in r/r Gastrointestinal Tumors (10hospital)
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors.
- Trial name
- NCT04960072
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Juncell Therapeutics
Melanoma, Non Small Cell Lung Cancer
Evaluation of a Pragmatic Approach to Adoptive Cell Therapy (ACT) Using an IL2 Analog (ANV419) vs High Dose IL2 After Tumor Infiltrating Lymphocytes (TIL) Therapy in Patients With Melanoma, NSCLC and Cervical Cancer (PragmaTIL)
Background: The presence of T-lymphocytes in resected tumor samples derived from long-term survival patients and the fact that reinvigoration of their functionality through the administration of specific immune-therapies can lead…
- Conditions
- Melanoma, Non Small Cell Lung Cancer, Cervical Cancer
- Trial name
- PragmaTIL (NCT06630611)
- Testing
- NMA-LD regimen, Tumor infiltrating lymphocytes adoptive cell therapy (TIL-ACT) infusion, High dose IL-2
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Recurrent Ovarian Cancer
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer.
- Trial name
- NCT07651124
- Testing
- autologous tumor-infiltrating lymphocytes
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- Yong Wha Moon
Triple-negative Breast Cancer
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC
Triple-negative breast cancer (TNBC) is a group of tumors that occurs mainly in young, premenopausal women and accounts for 10-20% of breast cancers.
- Trial name
- ETNA (NCT06078384)
- Testing
- Pembrolizumab 25 mg/ml, Paclitaxel injection
- Where
- 44 sites in France, Spain
- Volunteers
- 354 people
- Sponsor
- UNICANCER
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- RIOT 4B (NCT07443020)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2 (IL-2)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)